Page last updated: 2024-08-17

carbostyril and Idiopathic Parkinson Disease

carbostyril has been researched along with Idiopathic Parkinson Disease in 18 studies

Research

Studies (18)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (11.11)18.2507
2000's10 (55.56)29.6817
2010's5 (27.78)24.3611
2020's1 (5.56)2.80

Authors

AuthorsStudies
Choudhary, M; Malek, G1
Glenmullen, J; Mattison, DR; Moore, TJ1
Azorin, JM; Camus, V; Costentin, J; Crocq, MA; Daléry, J; Gliskman, J; Krebs, MO; Limosin, F; Millet, B1
Schwankhaus, J; Singh, S1
Chen, CK; Wu, JH1
Fujino, J; Tabushi, K; Tanaka, H; Taniguchi, N1
Chou, YH; Wang, SJ; Wu, CL; Yang, KC1
Bouckaert, F; De Schutter, P; Peuskens, J1
Miranda C, M; Retamal C, P1
Connemann, BJ; Schönfeldt-Lecuona, C1
Katz, IR1
López-Meza, E; Ramirez-Bermudez, J; Ruiz-Chow, A1
Ali, IM; Morris, HR; Wickremaratchi, M1
Berman, RM; Carson, WH; Factor, SA; Friedman, JH; Goetz, CG; Marcus, RN; Ondo, WG; Wojcieszek, J1
Singh Ajit, S1
Hurtig, HI; Weintraub, D1
Asin, KE; Domino, EF; Nikkel, A; Shiosaki, K1
Konieczny, J; Lorenc-Koci, E; Ossowska, K; Wolfarth, S1

Reviews

4 review(s) available for carbostyril and Idiopathic Parkinson Disease

ArticleYear
The Aryl Hydrocarbon Receptor: A Mediator and Potential Therapeutic Target for Ocular and Non-Ocular Neurodegenerative Diseases.
    International journal of molecular sciences, 2020, Sep-16, Volume: 21, Issue:18

    Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Biotransformation; Central Nervous System; Cytochrome P-450 Enzyme System; Disease Models, Animal; Eye Diseases; Eye Proteins; Gene Expression Regulation; Helix-Loop-Helix Motifs; Humans; Ligands; Mammals; Molecular Targeted Therapy; Multiple Sclerosis; Nerve Degeneration; Nerve Tissue Proteins; Neurodegenerative Diseases; Parkinson Disease; Polychlorinated Dibenzodioxins; Quinolones; Rats; Receptors, Aryl Hydrocarbon; Signal Transduction; Transcription, Genetic; Xenobiotics

2020
[Clinical potentialities and perspectives for the use of aripiprazole in other disorders than its classical indications. A critical analysis of the recent literature].
    L'Encephale, 2008, Volume: 34, Issue:2

    Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Borderline Personality Disorder; Depressive Disorder, Major; Humans; Mental Disorders; Neurodegenerative Diseases; Parkinson Disease; Piperazines; Quinolones; Schizophrenia; Substance-Related Disorders; Tourette Syndrome

2008
Optimizing atypical antipsychotic treatment strategies in the elderly.
    Journal of the American Geriatrics Society, 2004, Volume: 52, Issue:12 Suppl

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Controlled Clinical Trials as Topic; Dementia; Dibenzothiazepines; Humans; Olanzapine; Parkinson Disease; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles; Treatment Outcome

2004
Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodies.
    The American journal of psychiatry, 2007, Volume: 164, Issue:10

    Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Aripiprazole; Cholinesterase Inhibitors; Clozapine; Controlled Clinical Trials as Topic; Dibenzothiazepines; Humans; Lewy Body Disease; Male; Parkinson Disease; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones

2007

Other Studies

14 other study(ies) available for carbostyril and Idiopathic Parkinson Disease

ArticleYear
Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs.
    JAMA internal medicine, 2014, Volume: 174, Issue:12

    Topics: Adult; Aged; Aripiprazole; Benzothiazoles; Compulsive Behavior; Consumer Behavior; Dopamine Agonists; Drug Labeling; Female; Gambling; Humans; Hyperprolactinemia; Impulsive Behavior; Indoles; Male; Middle Aged; Parkinson Disease; Piperazines; Pramipexole; Quinolones; Receptors, Dopamine D3; Restless Legs Syndrome; Retrospective Studies; Sexual Behavior; United States; United States Food and Drug Administration

2014
Olfactory disturbance in Parkinson disease.
    Archives of neurology, 2009, Volume: 66, Issue:6

    Topics: Aged; Anticonvulsants; Antiparkinson Agents; Antipsychotic Agents; Aripiprazole; Biomarkers; Brain; Cognition Disorders; Constipation; Diagnosis, Differential; Disease Progression; Electroencephalography; Hallucinations; Humans; Levetiracetam; Lewy Body Disease; Male; Olfactory Pathways; Parkinson Disease; Piperazines; Piracetam; Quinolones; REM Sleep Behavior Disorder; Treatment Failure; Tremor

2009
Improvement of risperidone-related tardive parkinsonism with a switch to aripiprazole.
    Progress in neuro-psychopharmacology & biological psychiatry, 2009, Oct-01, Volume: 33, Issue:7

    Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Female; Humans; Middle Aged; Parkinson Disease; Piperazines; Quinolones; Risperidone

2009
Effectiveness of aripiprazole in a patient with presumed idiopathic Parkinson's disease and chronic paranoid schizophrenia.
    Psychiatry and clinical neurosciences, 2010, Volume: 64, Issue:1

    Topics: Antiparkinson Agents; Antipsychotic Agents; Aripiprazole; Chronic Disease; Drug Interactions; Female; Humans; Levodopa; Middle Aged; Parkinson Disease; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia, Paranoid

2010
Aripiprazole can treat psychotic features but not motor symptoms of Parkinson's disease: evidence from a SPECT study.
    Progress in neuro-psychopharmacology & biological psychiatry, 2011, Jan-15, Volume: 35, Issue:1

    Topics: Antipsychotic Agents; Aripiprazole; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Middle Aged; Parkinson Disease; Piperazines; Protein Binding; Psychotic Disorders; Quinolones; Tomography, Emission-Computed, Single-Photon

2011
[Aripiprazole-induced parkinsonism in a 64-year-old female patient diagnosed with bipolar disorder].
    Tijdschrift voor psychiatrie, 2011, Volume: 53, Issue:5

    Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Female; Humans; Middle Aged; Parkinson Disease; Piperazines; Quinolones

2011
[Potentiation of Aripiprazole extrapiramidal adverse effects with the concomitant use of serotonin selective reuptake inhibitors].
    Revista medica de Chile, 2011, Volume: 139, Issue:11

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors

2011
Aripiprazole and Parkinson's disease psychosis.
    The American journal of psychiatry, 2004, Volume: 161, Issue:2

    Topics: Aged; Antipsychotic Agents; Aripiprazole; Dopamine Agonists; Dose-Response Relationship, Drug; Humans; Levodopa; Male; Parkinson Disease; Piperazines; Psychoses, Substance-Induced; Quinolones

2004
Aripiprazole in psychosis associated with Parkinson's disease.
    The Journal of neuropsychiatry and clinical neurosciences, 2005,Summer, Volume: 17, Issue:3

    Topics: Aged; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Mental Disorders; Middle Aged; Parkinson Disease; Piperazines; Psychiatric Status Rating Scales; Quinolones

2005
Aripiprazole associated with severe exacerbation of Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:9

    Topics: Antipsychotic Agents; Aripiprazole; Dyskinesia, Drug-Induced; Female; Humans; Middle Aged; Neurologic Examination; Parkinson Disease; Parkinsonian Disorders; Piperazines; Psychotic Disorders; Quinolones

2006
Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.
    Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:12

    Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Dose-Response Relationship, Drug; Drug Tolerance; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Parkinson Disease; Pilot Projects; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Severity of Illness Index; Time Factors

2006
Does aripiprazole have a role in treating cognitive impairment in Parkinson's disease?
    The Journal of neuropsychiatry and clinical neurosciences, 2007,Spring, Volume: 19, Issue:2

    Topics: Acetylcholine; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Drug Administration Schedule; Humans; Male; Middle Aged; Parkinson Disease; Piperazines; Quinolones; Serotonin

2007
The selective dopamine D1 receptor agonist A-86929 maintains efficacy with repeated treatment in rodent and primate models of Parkinson's disease.
    The Journal of pharmacology and experimental therapeutics, 1997, Volume: 281, Issue:1

    Topics: Analysis of Variance; Animals; Antiparkinson Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Macaca nemestrina; Male; Parkinson Disease; Pyridines; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Rotation; Tetrahydronaphthalenes; Thiophenes

1997
The role of striatal glutamate receptors in models of Parkinson's disease.
    Amino acids, 1998, Volume: 14, Issue:1-3

    Topics: Animals; Corpus Striatum; Disease Models, Animal; Dizocilpine Maleate; Electromyography; Excitatory Amino Acid Antagonists; Haloperidol; Kynurenic Acid; Parkinson Disease; Quinolones; Rats; Receptors, N-Methyl-D-Aspartate; Reserpine

1998